December 9, 2022

Company Name: AnGes Inc.

Presentative: Ei Yamada, President & CEO

Notice on the Submission of a Marketing Authorization Application in Israel for HGF Gene Therapy Product "Collategene®", by our partner company, Kamada

AnGes Inc. is pleased to announce that Kamada has submitted an application to the Israeli Ministry of Health for marketing authorization of Collategene, which has been accepted.

We signed a basic agreement with Kamada in February 2019 for an exclusive Israeli marketing license for Collategene, an HGF gene therapy product for the treatment of chronic arterial occlusive ulcers.

We will not receive a lump sum payment as a result of this application.

1. About Collategene

Collategene is the main project we have been working on since its establishment and is the first gene therapeutic product in Japan to receive conditional and time-limited manufacturing and marketing approval in Japan for the improvement of ulcers in chronic arterial occlusive disease on March 26, 2019.

Collategene is a plasmid DNA expressing Hepatocyte Growth Factor (HGF), which was discovered in the liver, the organ with the highest regenerative capacity. This improves the ischemic condition.

HGF plays a major role in the formation and regeneration of various organs and tissues in the body, including blood vessels, lymph vessels, and nerves, as well as the liver. Focusing on the ability of HGF to "regenerate blood vessels," we have developed and commercialized HGF as a therapeutic agent with an unprecedented action of "regenerating blood vessels" for ischemic diseases in which blood vessels are clogged and blood flow is impaired.

2. About Kamada

Head Office Location	2 Holzman Street, Weizmann Science Park, Rehovot 7670402, Israel
Representative	Amir London（CEO）
Establishment	1990 (Listed on the Israeli stock market in 2005 and on the NASDAQ market in the U.S. in 2013)
Summary	Kamada Ltd. (“Kamada”) is a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, with a diverse portfolio of marketed products, a robust

(Note)This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translation and the Japanese original, the original shall prevail.

	development pipeline and industry-leading manufacturing capabilities. Kamada's strategy is focused on driving profitable growth from our current commercial activities as well as our manufacturing and development expertise in the plasma-derived biopharmaceutical market. Kamada's commercial products portfolio includes its developed and FDA approved products GLASSIA® and KEDRAB® as well as its recently acquired FDA approved plasma-derived hyperimmune products CYTOGAM®, HEPAGAM B®, VARIZIG® and WINRHO®SDF. Kamada has additional four plasma-derived products which are registered in markets outside the U.S. Kamada distributes its commercial products portfolio directly, and through strategic partners or third-party distributors in more than 30 countries, including the U.S., Canada, Israel, Russia, Brazil, Argentina, India and other countries in Latin America and Asia. Kamada has a diverse portfolio of development pipeline products including an inhaled AAT for the treatment of AAT deficiency for which Kamada is currently conducting the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. Kamada leverages its expertise and presence in the Israeli pharmaceutical market to distribute in Israel more than 20 products that are manufactured by third parties and have recently added eleven biosimilar products to its Israeli distribution portfolio, which, subject to EMA and the Israeli MOH approvals, are expected to be launched in Israel through 2028. FIMI Opportunity Fund, the leading private equity investor in Israel, is Kamada's lead shareholder, beneficially owning approximately 21% of the outstanding ordinary shares.

3. Future outlook

The application for manufacturing and marketing approval in Israel was delayed significantly from the original schedule due to the impact of the covid-19.Accordingly, the timing of regulatory approval and reimbursement in Israel has not been determined at this time.

AnGes is preparing to begin providing the NPP* to patients in Israel under an agreement with Kamada prior to obtaining approval.

The impact of this application on the consolidated financial results for the fiscal year ending December 31, 2022 is expected to be immaterial. If any event occurs that requires disclosure, such as the progress of the application and its impact on our consolidated business results, we will promptly disclose such information.

*NPP（Named Patient Program）: A program in which a manufacturer or distributor registers a patient and provides the drug individually to a physician who requests its use in countries where the applicable drug has not been approved or reimbursement price has not been determined.

(Note)This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translation and the Japanese original, the original shall prevail.